Document is current
Any future updates will be listed below
-
Authors
Feuerstadt, Paul https://orcid.org/0000-0002-7643-9576
Allegretti, Jessica R.
Dubberke, Erik R.
Guo, Amy
Harvey, Adam
Yang, Min https://orcid.org/0000-0002-4864-6658
Garcia-Horton, Viviana https://orcid.org/0000-0003-0835-800X
Fillbrunn, Mirko
Tillotson, Glenn
Bancke, Lindy L.
LaPlante, Kerry
Garey, Kevin W.
Khanna, Sahil
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03244644 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
https://doi.org/10.1007/s40265-022-01797-x
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
https://doi.org/10.1007/s40121-023-00907-w
-
Funding
Funding for this research was provided by:
Ferring Pharmaceuticals
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 14 December 2023
First Online: 18 January 2024
Declarations
:
: Min Yang, Viviana Garcia-Horton, and Mirko Fillbrunn are employees of Analysis Group, Inc., which received payment from Ferring Pharmaceuticals for participation in this research. Amy Guo is an employee of Ferring Pharmaceuticals. Adam Harvey and Lindy L. Bancke are employees of Rebiotix Inc., a Ferring Company. Paul Feuerstadt is a consultant for and a member of the speakers’ bureau and advisory board of Ferring Pharmaceuticals/Rebiotix Inc.; is a consultant for and advisory board member of Seres Therapeutics; is a consultant for Merck and Co.; and is on the advisory board of Takeda Pharmaceuticals. Glenn Tillotson is an employee of GST Micro LLC and a consultant for Ferring Pharmaceuticals, Spero, and Taro Pharmaceuticals. Kevin W. Garey is a consultant for Ferring Pharmaceuticals, and has received research grant from Acurx, Summit, Paratek Pharmaceuticals, and Seres Health. Erik R. Dubberke is a consultant for and received research grants from Ferring and Pfizer; is a consultant for Abbott, Merck, Seres, and Summit; has received research grants from Synthetic Biologics; and is a member of the advisory board for Rebiotix. Kerry LaPlante has received research funding from Merck, is an advisor to Seres Therapeutics, and serves on the Advisory Board for Ferring Pharmaceuticals. Sahil Khanna receives research support from Rebioitx/Ferring, Vedanta, Finch, Seres Therapeutics, and Pfizer, and serves as a consultant for Probio Tech, LLC; Shire/Takeda, Niche and Immuron.
: All aspects of the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. As this analysis used de-identified clinical trial data, no institutional board review or patient consent was required for this study.
